NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) - PubMed (original) (raw)
Practice Guideline
NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN)
Miriam B Vos et al. J Pediatr Gastroenterol Nutr. 2017 Feb.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent chronic liver disease that occurs in the setting of insulin resistance and increased adiposity. It has rapidly evolved into the most common liver disease seen in the pediatric population and is a management challenge for general pediatric practitioners, subspecialists, and for health systems. In this guideline, the expert committee on NAFLD reviewed and summarized the available literature, formulating recommendations to guide screening and clinical care of children with NAFLD.
Conflict of interest statement
POTENTIAL CONFLICT OF INTEREST / FINANCIAL DISCLOSURE STATEMENT
MV has research funding from Resonance Health Inc, serves on a DSMB for Aegerion and as a consultant for Shire, Immuron, Intercept and Target Pharmasolutions. SD serves on a DMC for Novo Nordisk and consults for Sanofi. RK has research funding from Raptor. The remaining authors have no personal or financial conflicts of interest to declare.
Figures
Figure 1
An algorithm proposed by the ECON group. Further research is likely to alter the algorithm. The steps are suggested courses of action and should be interpreted within the clinical scenario of individual patients. Additional testing
for chronic liver diseases to consider:
- Screening labs: CBC with differential, AST, bilirubin (total, conjugated), alkaline phosphatase, GGT, INR, albumin, total protein, hemoglobin A1c
- Exclude infections (e.g. hepatitis A IgM, hepatitis B surface antigen, hepatitis C antibody, other chronic viral infections)
- Exclude endocrine disorders (TSH, free T4)
- Exclude autoimmune causes of ALT elevation (total IgA, total IgG and tissue transglutaminase antibody, anti-nuclear antibody, anti-smooth muscle antibody, anti-liver kidney microsomal antibody)
- Exclude genetic causes of ALT (ceruloplasmin and/or 24 hour urine copper, lysosomal acid lipase, alpha-1 antitrypsin phenotype)
- Imaging: Abdominal ultrasound to rule out anatomical abnormalities or assess features of portal hypertension, magnetic resonance imaging or spectroscopy to measure hepatic fat.
- Liver biopsy (histology, copper measurement, stain for microvesicular fat, assess fibrosis)
Red flags
for advanced liver disease
– chronic fatigue, GI bleeding, jaundice, splenomegaly, firm liver on exam, enlarged left lobe of the liver, low platelets, low white blood cell count, elevated direct bilirubin, elevated international normalized ratio (INR), long history of elevated liver enzymes (> 2 years).
Figure 2
Treatments for pediatric NAFLD
Comment in
- Response to the Letters Regarding the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition NAFLD Guidelines.
Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R, Mouzaki M, Sathya P, Schwimmer JB, Sundaram SS, Xanthakos SA. Vos MB, et al. J Pediatr Gastroenterol Nutr. 2017 Nov;65(5):e115-e116. doi: 10.1097/MPG.0000000000001731. J Pediatr Gastroenterol Nutr. 2017. PMID: 29059122 No abstract available. - Please Do Not Forget Muscle Disease When Evaluating Elevated Transaminases.
Noritz G. Noritz G. J Pediatr Gastroenterol Nutr. 2017 Nov;65(5):e114. doi: 10.1097/MPG.0000000000001669. J Pediatr Gastroenterol Nutr. 2017. PMID: 29064930 No abstract available. - Screening for NAFLD in Children: Do We Know the Optimal ALT Cut-off?
Koot BGP, Benninga MA. Koot BGP, et al. J Pediatr Gastroenterol Nutr. 2017 Nov;65(5):e115. doi: 10.1097/MPG.0000000000001667. J Pediatr Gastroenterol Nutr. 2017. PMID: 29064932 No abstract available.
Similar articles
- Management of NAFLD: a stage-based approach.
Rinella ME, Sanyal AJ. Rinella ME, et al. Nat Rev Gastroenterol Hepatol. 2016 Apr;13(4):196-205. doi: 10.1038/nrgastro.2016.3. Epub 2016 Feb 24. Nat Rev Gastroenterol Hepatol. 2016. PMID: 26907882 Review. - Nonalcoholic Fatty Liver Disease: Pathophysiology and Management.
Carr RM, Oranu A, Khungar V. Carr RM, et al. Gastroenterol Clin North Am. 2016 Dec;45(4):639-652. doi: 10.1016/j.gtc.2016.07.003. Epub 2016 Oct 13. Gastroenterol Clin North Am. 2016. PMID: 27837778 Free PMC article. Review. - Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T; Japanese Society of Gastroenterology; Japan Society of Hepatology. Watanabe S, et al. J Gastroenterol. 2015 Apr;50(4):364-77. doi: 10.1007/s00535-015-1050-7. Epub 2015 Feb 24. J Gastroenterol. 2015. PMID: 25708290 - Urinary thiodiglycolic acid is associated with increased risk of non-alcoholic fatty liver disease in children living near a petrochemical complex.
Wang CW, Chuang HY, Liao KW, Yu ML, Dai CY, Chang WT, Tsai CH, Chiang HC, Huang PC. Wang CW, et al. Environ Int. 2019 Oct;131:104978. doi: 10.1016/j.envint.2019.104978. Epub 2019 Jul 18. Environ Int. 2019. PMID: 31325714 - Nonalcoholic fatty liver disease: Evolving paradigms.
Lonardo A, Nascimbeni F, Maurantonio M, Marrazzo A, Rinaldi L, Adinolfi LE. Lonardo A, et al. World J Gastroenterol. 2017 Sep 28;23(36):6571-6592. doi: 10.3748/wjg.v23.i36.6571. World J Gastroenterol. 2017. PMID: 29085206 Free PMC article. Review.
Cited by
- Cardiometabolic risk in children and adolescents with obesity: a position paper of the Italian Society for Pediatric Endocrinology and Diabetology.
Valerio G, Di Bonito P, Calcaterra V, Cherubini V, Corica D, De Sanctis L, Di Sessa A, Faienza MF, Fornari E, Iughetti L, Licenziati MR, Manco M, Del Giudice EM, Morandi A, Salerno M, Street ME, Umano GR, Wasniewska M, Maffeis C. Valerio G, et al. Ital J Pediatr. 2024 Oct 8;50(1):205. doi: 10.1186/s13052-024-01767-x. Ital J Pediatr. 2024. PMID: 39380079 Free PMC article. Review. - Recorded diagnosis of overweight/obesity in primary care is linked to obesity care performance rates.
Shalitin S, Phillip M, Yackobovitch-Gavan M. Shalitin S, et al. Pediatr Res. 2024 Oct 8. doi: 10.1038/s41390-024-03619-0. Online ahead of print. Pediatr Res. 2024. PMID: 39375505 - Efficacy of the Mediterranean diet in treating metabolic dysfunction-associated steatotic liver disease (MASLD) in children and adolescents: a systematic review and meta-analysis.
Jamil A, Chivese T, Elshaikh U, Sendall M. Jamil A, et al. BMC Public Health. 2024 Oct 3;24(1):2701. doi: 10.1186/s12889-024-19378-w. BMC Public Health. 2024. PMID: 39363272 Free PMC article. - Converging Pathways between Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Diabetes in Children.
Faienza MF, Farella I, Khalil M, Portincasa P. Faienza MF, et al. Int J Mol Sci. 2024 Sep 14;25(18):9924. doi: 10.3390/ijms25189924. Int J Mol Sci. 2024. PMID: 39337412 Free PMC article. Review. - The phenotype of the pediatric patient with Cushing syndrome but without obesity.
Padilla C, Stratakis CA, Tatsi C. Padilla C, et al. Eur J Endocrinol. 2024 Sep 30;191(4):399-406. doi: 10.1093/ejendo/lvae114. Eur J Endocrinol. 2024. PMID: 39288098
References
- Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547–55. - PubMed
- Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005–23. - PubMed
- Vajro P, Lenta S, Socha P, Dhawan A, McKiernan P, Baumann U, et al. Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr. 2012;54(5):700–13. - PubMed
- Louthan MV, Theriot JA, Zimmerman E, Stutts JT, McClain CJ. Decreased prevalence of nonalcoholic fatty liver disease in black obese children. Journal of pediatric gastroenterology and nutrition. 2005;41(4):426–9. - PubMed
- Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118(4):1388–93. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 DK088831/DK/NIDDK NIH HHS/United States
- U01 DK061731/DK/NIDDK NIH HHS/United States
- P30 DK078392/DK/NIDDK NIH HHS/United States
- R01 DK100314/DK/NIDDK NIH HHS/United States
- R01 DK088925/DK/NIDDK NIH HHS/United States
- R56 DK088831/DK/NIDDK NIH HHS/United States
- R03 DK096157/DK/NIDDK NIH HHS/United States
- R13 DK107243/DK/NIDDK NIH HHS/United States
- U01 DK061734/DK/NIDDK NIH HHS/United States
- UL1 TR001425/TR/NCATS NIH HHS/United States
- P30 DK048522/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical